RÉSUMÉ
In experimental animals with tumors it was studied antitumor activity of spirocyclic hydroxamic acids which could be classified as targeted agents as their target was enzyme histonedeacetylase, which was involved in the neoplastic process. The results showed that the hydroxamic acids were chemosensitizers for anticancer agents increasing their efficacy and enabling the researchers to reduce significantly the therapeutic dose. Also it was showed that hydroxamic acid, containing nitrogen mustard, was effective in the action on tumors with phenotype and genotype of multidrug resistance.
Sujet(s)
Antinéoplasiques/pharmacologie , Multirésistance aux médicaments/effets des médicaments et des substances chimiques , Résistance aux médicaments antinéoplasiques/effets des médicaments et des substances chimiques , Acides hydroxamiques/pharmacologie , Tumeurs expérimentales/traitement médicamenteux , Animaux , Antinéoplasiques/usage thérapeutique , Cyclophosphamide/administration et posologie , Inhibiteurs de désacétylase d'histone , Acides hydroxamiques/usage thérapeutique , Leucémie P388/traitement médicamenteux , Méthotrexate/administration et posologieRÉSUMÉ
It has been showed that the introduction of nitrocompounds (as nitic oxide donors) in to the compositions of cyclophosphamide and hydroxamic acids for curing animals having leukemia P-388 increased duration of life by 290%. Thereby 40% of animals have recovered. The therapeutic dose cyclophosphamide have been reduced by 6 times.